1,045
Views
0
CrossRef citations to date
0
Altmetric
Infectious Diseases

Healthcare costs among patients with newly diagnosed helicobacter pylori infection in the United States: a linked claims-EHR study

ORCID Icon, ORCID Icon, , , , ORCID Icon & ORCID Icon show all
Pages 1227-1236 | Received 03 Aug 2023, Accepted 22 Sep 2023, Published online: 09 Oct 2023

References

  • Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–429. doi: 10.1053/j.gastro.2017.04.022.
  • Crowe SE. Helicobacter pylori infection. N Engl J Med. 2019;380(12):1158–1165. doi: 10.1056/NEJMcp1710945.
  • de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180-90–e190. doi: 10.1016/S2214-109X(19)30488-7.
  • Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–239. doi: 10.1038/ajg.2016.563.
  • Mapel D, Roberts M, Overhiser A, et al. The epidemiology, diagnosis, and cost of dyspepsia and Helicobater pylori gastritis: a case–control analysis in the Southwestern United States. Helicobacter. 2013;18(1):54–65. doi: 10.1111/j.1523-5378.2012.00988.x.
  • Solanki S, Chakinala RC, Haq KF, et al. Inpatient burden of gastric cancer in the United States. Ann Transl Med. 2019;7(23):772–772. doi: 10.21037/atm.2019.11.54.
  • Kanotra R, Ahmed M, Patel N, et al. Seasonal variations and trends in hospitalization for peptic ulcer disease in the United States: a 12-year analysis of the nationwide inpatient sample. Cureus. 2016;8(10):e854. doi: 10.7759/cureus.854.
  • Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156(1):254–272.e11. doi: 10.1053/j.gastro.2018.08.063.
  • Shah S, Hubscher E, Pelletier C, et al. Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure. Expert Rev Gastroenterol Hepatol. 2022;16(4):341–357. doi: 10.1080/17474124.2022.2056015.
  • Measuring price change in the CPI: medical care. Consumer price index. Published March 16, 2022. Accessed September 20, 2022. https://www.bls.gov/cpi/factsheets/medical-care.htm.
  • Onukwugha E, Bergtold J, Jain R. A primer on marginal effects-part II: health services research applications. Pharmacoeconomics. 2015;33(2):97–103. doi: 10.1007/s40273-014-0224-0.
  • Otani K, Baden WW. Healthcare cost and predictive factors: high- and low-utilization model development. Health Mark Q. 2009;26(3):198–208. doi: 10.1080/07359680903263599.
  • Song X, Cai C, Jin Q, et al. The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: a systematic review and meta-analysis. Helicobacter. 2021;26(2):e12781. doi: 10.1111/hel.12781.
  • Kumar S, Metz DC, Ellenberg S, et al. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology. 2020;158(3):527–536.e7. doi: 10.1053/j.gastro.2019.10.019.
  • Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut. 2005;54(6):735–738. doi: 10.1136/gut.2004.056549.
  • Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69(12):2113–2121. doi: 10.1136/gutjnl-2020-320839.
  • Shah SC, Bonnet K, Schulte R, et al. Helicobacter pylori management is associated with predominantly negative patient experiences: results from a focused qualitative analysis. Dig Dis Sci. 2022;67(9):4387–4394. doi: 10.1007/s10620-021-07320-8.